Member Info for BuenaVista

I came across this just now. The full text is freely available online.

The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors
https://aacrjournals.org/clincancerres/article/11/24/8782/188867/The-Distribution-of-the-Anticancer-Drug

"Abstract

"Purpose: Anticancer drugs gain access to solid tumors via the circulatory system and must penetrate the tissue to kill cancer cells. Here, we study the distribution of doxorubicin in relation to blood vessels and regions of hypoxia in solid tumors of mice.

"Experimental Design: The distribution of doxorubicin was quantified by immunofluorescence in relation to blood vessels (recognized by CD31) of murine 16C and EMT6 tumors and human prostate cancer PC-3 xenografts. Hypoxic regions were identified by injection of EF5.

"Results: The concentration of doxorubicin decreases exponentially with distance from tumor blood vessels, decreasing to half its perivascular concentration at a distance of about 40 to 50 µm, The mean distance from blood vessels to regions of hypoxia is 90 to 140 µm in these tumors. Many viable tumor cells are not exposed to detectable concentrations of drug following a single injection.

"Conclusions: Limited distribution of doxorubicin in solid tumors is an important and neglected cause of clinical resistance that is amenable to modification. The technique described here can be adapted to studying the distribution of other drugs within solid tumors and the effect of strategies to modify their distribution."

A, but that's because of my stage of life.
Would be B if I was younger.

I'm really worried now. So many speculative oil and mineral companies have collapsed. What does this mean for Avacta????? Surely a death spiral!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!1

There will only be a rerate when there's a clear path to revenue. The visionary will see that with excellent safety and tolerability data and very strong initial indications of efficacy (biopsies, tumour measurements, obvious reduced or lack of doxorubicin side-effects) and load up. The dullards will wait until the ship is sailing.

The 200mg/m² one? That would be 135mg/m² doxorubicin equivalent, so 3 cycles would have been possible.

I suggest that 3 data points are the absolute minimum for obtaining a meaningful graph.

At 280mg/m² AVA6000, 3 cycles would take the total administered doxorubicin to 567mg/m² which is higher than the top of the 450-550 doxorubicin CTLD range. So if there are to be dose escalations (plural), that doxorubicin CTLD limit would have to go.

Except that a DE to, say, 240mg/m², which is equivalent to 162mg/m² doxorubicin equivalent would only allow two cycles (from a starting point of no prior doxorubicin) to keep under the 450mg/m² CTLD, if indeed 450 is the limit, and they surely want to be going even higher if the intention is to find MTD - "higher dose cohortS" plural.
I just don't think it is possible/useful to escalate the dose within the constraint of doxorubicin's traditional CTLD. And, speaking personally, if I wanted to up the allowable CTLD of AVA6000-delivered doxorubicin I'd also want to increase the frequency of administration (shorten the cycle time) as the body doesn't need the 3 weeks to recover from doxorubicin-indiuced side-effects.
Such changes would need to go to MHRA, FDA and their respective ethics committees, and that takes time. If the starting gun for this was back in November/early December, then a decision is surely due soon (expected by Avacta by Science Day?) according to the FDA (at least) 30 day or 60 day or whatever it is time limit for responding.

I just put it there for people to read, and listen to if they want to check on the veracity of my transcription.

I don't give a flying fugg about the FUDders. They have no interest in Avacta or AVA6000 succeeding, only in their own greed. It's up to everyone whether they want to assign any value to anything such people write rather than doing their own research and having faith in their own judgement.

As for Science Day, it will be what it will be. Nothing said or done then will affect the results obtained so far.

.co.uk of course

https://www.**********.co.uk/articles/alastair-smith-of-avacta-successful-completion-of-fourth-dose-escalation-in-ava6000-phase-1-clinical-study-5e35ec7/

v o x m a r k e t s .com

@ 6:35

"The data are unequivocal. I'm delighted to say that doxorubicin IS [his emphasis] being released in the tumour tissue and at significant levels, therapeutically relevant levels. So, we know that from analysing tumour biopsies from six patients across several of the cohorts. We're seeing doxorubicin in ALL [his emphasis] of the tumour biopsies that we've taken, and it's clear that AVA6000 can deliver a therapeutically meaningful dose of doxorubicin into the tumour tissue whilst, when we measure in the bloodstream at exactly the same time, the concentration is very much lower, as we would hope."

That's unequivocal. Anyone who wants to dispute any of that should take it up with Alan personally as arguing here against what Alan said is just noise.

Well apparently a Science Day was an annual thing until covid., or so I've read here.

I don't know the format of previous ones and it doesn't really matter. For this one, Avacta have news to impart - otherwise they would have stuck with the original November tmeframe (itself delayed from September) - and are inviting KOLs in oncology to share their knowledge.

We've had no official notification of who the KOLs will be, and there's no reason why we should be notified. Maybe the invitees have been told, maybe they haven't; it doesn't matter either way.

There are similar schemes from other regulatory authorities. AVA6000 should be eligible for these as well.

MHRA's
Orphan medicinal products: https://www.gov.uk/guidance/orphan-medicinal-products-in-great-britain
and
ILAP: https://www.gov.uk/guidance/innovative-licensing-and-access-pathway

EMA's
Orphan designation: https://www.ema.europa.eu/en/human-regulatory/research-development/orphan-designation-research-development
and
PRIME: https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines

And then FUDder-in-chief, NDN hiding under the name Thornogson, arrives...

Why do you think AVA6000 is excreted more quickly by humans than by mouse if you don't know the data?

Similarly, why do you expect to double or treble your money this year if you haven't seen the data to know how well it works?

You're inconsistent in everything except your FUDding.

Riesgo isn't invested here. Gawd knows why it hangs around the BB. Just bin it.

Riesgo, if you are concerned you must sell and f off if invested. If not invested, just f off.

But of course you aren't invested and no one believes you are. Just give it up and f off.

Yes a long maths lesson. The end result of a scientific discussion without dissenting views?

Thanks for the heads up about the group that produces that stuff. Better to have disagreements here than an echo chamber I think.

As I wrote earlier, I've got access to the #AVCT Avacta Investor Information group. I notice that there's more than a bit of crossposting there of stuff from here including a piece I wrote, uncredited and a bloody cheek as I wrote it here. It seems some of Ophidian's and RAH's pieces appear there, credited. Are they these the same person?

Afternoon slide to yeboha's 162?

That's it then. Loss can now be claimed.

From the RNS about Launch Diagnostics: "Since FY19, the gross margin in total sales has consistently been in the range 44-50% across all products."

Always useful to have a foothold in France to get French government contracts. Long may it continue.